Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- EPICIndependent statistical analysis of Engaging Patients With Mental Disorders From the ED in Outpatient Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- EPICAIndependent statistical analysis of Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- EpiCeram for Skin Protection in Healthcare Workers: Complete Statistical AnalysisIndependent statistical analysis of EpiCeram for Skin Protection in Healthcare Workers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04793711).
- EPICSIndependent statistical analysis of Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Epidemiological Study of the COVID-2019 in Participating Organizations.: Complete Statistical AnalysisIndependent statistical analysis of Epidemiological Study of the COVID-2019 in Participating Organizations.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05043142).
- Epidemiology and Prevention of Methicillin Resistant Staphylococcus Aureus (MRSA) Transmission in the Community: Complete Statistical AnalysisIndependent statistical analysis of Epidemiology and Prevention of Methicillin Resistant Staphylococcus Aureus (MRSA) Transmission in the Community: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Epidemiology of Acute Kidney Injury in England – 1998 to 2013: Complete Statistical AnalysisIndependent statistical analysis of Epidemiology of Acute Kidney Injury in England - 1998 to 2013: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Epidemiology of Depression, Anxiety, and Cognitive Impairment: Complete Statistical AnalysisIndependent statistical analysis of Epidemiology of Depression, Anxiety, and Cognitive Impairment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00717041).
- Epiduo Pediatric Acne Study: Complete Statistical AnalysisIndependent statistical analysis of Epiduo Pediatric Acne Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01138735).
- Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- EPOIndependent statistical analysis of Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00626574).
- EPOCHIndependent statistical analysis of An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer: Complete Statistical AnalysisIndependent statistical analysis of Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- EQUATEIndependent statistical analysis of A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- EQUATORIndependent statistical analysis of Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- EQUIPIndependent statistical analysis of A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- EQUIP-2Independent statistical analysis of Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00137280).
- EQUIPED-ADRDIndependent statistical analysis of Enhanced Quality in Primary Care for Elders With Diabetes and Dementia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- EQUIPPEDIndependent statistical analysis of Reducing Potentially Inappropriate Medication Prescribing for Older Patients in the ED: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- EQUIPSIndependent statistical analysis of Enhancing Quality Interventions Promoting Healthy Sexuality: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01818791).
- ERADICATE HpIndependent statistical analysis of ERADICATE Hp - Treating Helicobacter Pylori With RHB-105: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01980095).
- ERASE-MIIndependent statistical analysis of Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Erector Spinae Plane vs. Paravertebral Nerve Block for Thoracic Surgery: Complete Statistical AnalysisIndependent statistical analysis of Erector Spinae Plane vs. Paravertebral Nerve Block for Thoracic Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03758261).
- EREPIndependent statistical analysis of Emotion Regulation and Emotion Perception: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03790878).
- Eribulin in HER2 Negative Metastatic BrCa: Complete Statistical AnalysisIndependent statistical analysis of Eribulin in HER2 Negative Metastatic BrCa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01827787).
- Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON): Complete Statistical AnalysisIndependent statistical analysis of Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00476476).
- Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00970502).
- Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005): Complete Statistical AnalysisIndependent statistical analysis of Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02099110).
- ESBA105 in Patients With Severe Dry Eye: Complete Statistical AnalysisIndependent statistical analysis of ESBA105 in Patients With Severe Dry Eye: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01338610).
- EscapeIndependent statistical analysis of Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ESCAPEIndependent statistical analysis of Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ESCAPE-TRDIndependent statistical analysis of A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major…
- ESCAPEDIndependent statistical analysis of Comparison of Patient Centered Outcomes for People With Sickle Cell Disease in the Acute Care Setting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Escitalopram Effects on CSF Amyloid Beta: Complete Statistical AnalysisIndependent statistical analysis of Escitalopram Effects on CSF Amyloid Beta: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02161458).
- Escitalopram to Placebo in Patients With Localized Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Escitalopram to Placebo in Patients With Localized Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05289830).